Registration Dossier
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 255-180-5 | CAS number: 41026-17-9
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Developmental toxicity / teratogenicity
Administrative data
- Endpoint:
- developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 19 June 2018 - 22 October 2018
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 018
- Report Date:
- 2019
Materials and methods
Test guideline
- Qualifier:
- according to
- Guideline:
- OECD Guideline 414 (Prenatal Developmental Toxicity Study)
- GLP compliance:
- yes (incl. certificate)
Test material
Reference
- Name:
- Unnamed
- Type:
- Constituent
- Test material form:
- other: Pale yellow solid block
- Details on test material:
- Identification: NPG-THPA Hemiester (TK12094)
Description: Pale yellow solid block
Batch: Colkb03
Purity: 96%
Expiry / Retest Date: 01 February 2021
Storage Conditions: Room temperature in the dark over silica gel
- Specific details on test material used for the study:
- SOURCE OF TEST MATERIAL
- Batch No.of test material: Colkb03
- Expiration date of the batch: 01 February 2021
- Purity: > 85 %
STABILITY AND STORAGE CONDITIONS OF TEST MATERIAL
- Storage condition of test material: Ambient temperature over silica gel in darkness
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Details on test animals and environmental conditions:
- TEST ANIMALS
- Weight at study initiation: 224 to 323g.
- Housing: Solid-floor polypropylene cages with stainless steel mesh lids furnished with softwood flakes
- Diet: ad libitum
- Water: ad libitum
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 ± 3 ºC
- Humidity (%): 50 ± 20 %
- Air changes (per hr): 15
- Photoperiod: 12 hrs dark / 12 hrs light
IN-LIFE DATES: From: 22 Jun 2018 To: 11 July 2018
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- propylene glycol
- Details on exposure:
- PREPARATION OF DOSING SOLUTIONS: For the purpose of the study, the test item was prepared at the appropriate concentrations in Propylene glycol. The stability and homogeneity of the test item formulations were determined. Bulk formulations were therefore prepared one occasion, divided into daily aliquots and stored at approximately 4 °C in the dark until the day of use.
VEHICLE
- Concentration in vehicle: 0, 20, 60, 150 mg/mL - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Samples were taken of each test item formulation and were analyzed for concentration of 2,2-dimethylpropane-1,3-diyl cyclohex-4-ene-1,2-dicarboxylate. The results indicate that the prepared formulations were within 100 to 103% of the nominal concentration and were acceptable for use on the study.
- Frequency of treatment:
- Daily
- Duration of test:
- from Day 3 to Day 19 of gestation
Doses / concentrationsopen allclose all
- Dose / conc.:
- 0 mg/kg bw/day
- Dose / conc.:
- 100 mg/kg bw/day
- Dose / conc.:
- 300 mg/kg bw/day
- Dose / conc.:
- 750 mg/kg bw/day
- No. of animals per sex per dose:
- 24
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: The dose levels were chosen based on previous toxicity data available toxicity data, including data from a Preliminary Oral (Gavage) Pre-Natal Development Toxicity Study in the Rat and a Fourteen Day Repeated Dose Oral (Gavage) Range-Finding Toxicity Study in the Rat.
- Other: The oral route was selected as the most appropriate route of exposure, based on the physical properties of the test item, and the results of the study are believed to be of value in predicting the likely toxicity of the test item to man.
Examinations
- Maternal examinations:
- DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: Once daily during the gestation period. Additionally, during the dosing period, observations were recorded immediately before and soon after dosing and one hour post dosing.
BODY WEIGHT: Yes
- Time schedule for examinations: On days 3, 4, 5, 8, 11, 14 and 17 of gestation. Body weights were also recorded for animals at terminal kill (Day 20).
POST-MORTEM EXAMINATIONS: Yes
- Sacrifice on gestation day 20
- Organs examined: Kidney, Ovaries, Uteri - Ovaries and uterine content:
- The ovaries and uterine content was examined after termination: Yes
Examinations included:
- Gravid uterus weight: Yes
- Number of corpora lutea: Yes
- Number of implantations: Yes - Fetal examinations:
- - External examinations: Yes
- Soft tissue examinations: Yes
- Skeletal examinations: Yes
Results and discussion
Results: maternal animals
General toxicity (maternal animals)
- Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Food efficiency:
- effects observed, treatment-related
- Description (incidence and severity):
- At 750 mg/kg bw/day, mean food consumption was statistically significantly lower than control from the start of treatment (Day 3 of gestation) until Day 8 of gestation. Thereafter, food intake during gestation was considered to be similar to control until termination on Day 20 of gestation.
There was no effect of treatment on food consumption during gestation at 100 or 300 mg/kg bw/day. - Gross pathological findings:
- no effects observed
Effect levels (maternal animals)
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 750 mg/kg bw/day
- Based on:
- test mat.
- Basis for effect level:
- clinical signs
- mortality
- body weight and weight gain
- food efficiency
- gross pathology
Results (fetuses)
- Fetal body weight changes:
- no effects observed
- Reduction in number of live offspring:
- no effects observed
- Changes in sex ratio:
- no effects observed
- Changes in litter size and weights:
- no effects observed
- External malformations:
- no effects observed
- Skeletal malformations:
- no effects observed
- Visceral malformations:
- no effects observed
Effect levels (fetuses)
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 750 mg/kg bw/day
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- reduction in number of live offspring
- changes in sex ratio
- fetal/pup body weight changes
- changes in litter size and weights
- external malformations
- skeletal malformations
- visceral malformations
Overall developmental toxicity
- Key result
- Developmental effects observed:
- no
Applicant's summary and conclusion
- Conclusions:
- Based on these findings of this pre-natal study, a dosage of 750 mg/kg bw/day was regarded as a No Observed Adverse Effect Level (NOAEL) for the pregnant female.
The findings observed for fetuses at 750 mg/kg bw/day were considered to be unrelated to treatment and this dosage of 750 mg/kg bw/day was considered to represent at least a NOAEL, and most probably a No Observed Effect Level (NOEL), for the survival, growth and development of the conceptus. - Executive summary:
Introduction
The study was performed to investigate the effects of the test item on embryonic and fetal development following repeated daily administration by gavage to the pregnant female during Days 3 to 19 of gestation, including the period of organogenesis.
The study was designed to comply with the following guidelines:
· US EPA Health Effects Test Guideline OPPTS 870.3700, ‘Prenatal Developmental Toxicity Study’ (August 1998)
· Japanese Ministry of Agriculture, Forestry and Fisheries Testing guidelines for Toxicology studies, 12 Nousan No 8147, (24 November 2000)
· OECD Guidelines for Testing of Chemicals, No 414, ‘Prenatal Developmental Toxicity Study’ (adopted 22 January 2001)
· Commission Regulation (EC) No 440/2008 of 30 May 2008 test methods pursuant to Regulations (EC) No 1907/2006 of the European Parliament and of the Council on the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH)
Methods
The test item was administered by gavage to three groups each of twenty-four time mated Sprague-Dawley Crl:CD®(SD) IGS BR strain rats, between Days 3 and 19 of gestation inclusive at dose levels of 100, 300 and 750 mg/kg bw/day. A further group of twenty-four time mated females was exposed to the vehicle only (Propylene Glycol) over the same treatment period to serve as a control.
Clinical signs, body weight change, food and water consumptions were monitored during the study.
All females were terminated on Day 20 of gestation and subjected to gross necropsy including examination of the uterine contents. The number of corpora lutea, number, position and type of implantation, placental weights, fetal weight, sex and external and internal macroscopic appearance were recorded. Half of each litter were examined for detailed skeletal development and the remaining half were subjected to detailed visceral examination.
Results…….
Mortality
There were no unscheduled deaths on the study.
Clinical Observations
Clinical signs did not indicate any systemic effect of treatment at 100, 300 or 750 mg/kg bw/day.
Body Weight
At 750 mg/kg bw/day, mean body weight gain was statistically significantly lower than control on the first day of treatment, thereafter body weight gain was unaffected by treatment and mean overall body weight gain at termination, including when adjusted for the contribution of the gravid uterus, was similar to control.
There was no effect of treatment on body weight gain during gestation, including when values were adjusted for the contribution of the gravid uterus, at 100 or 300 mg/kg bw/day.
Food Consumption
At 750 mg/kg bw/day, mean food consumption was statistically significantly lower than control from the start of treatment to Day 8 of gestation.
There was no effect of treatment on food consumption during gestation at 100 or 300 mg/kg bw/day.
Water Consumption
Daily visual inspection of water bottles did not reveal any overt intergroup differences.
Post Mortem Studies
Macroscopic necropsy findings observed for adult animals did not indicate any effect of treatment at 100, 300 or 750 mg/kg bw/day.
Litter Data and Litter Placental and Fetal Weights
There was no effect of maternal treatment on pre-implantation loss, number of implantations, subsequent embryofoetal survival, litter size or sex ratio on Day 20 of gestation at 100, 300 or 750 mg/kg bw/day.
Fetal Examination
External Examination
The type, incidence and distribution of external findings at 100, 300 and 750 mg/kg bw/day did not indicate any effect on fetal development, although it was noted that one fetus at 300 mg/kg bw/day showed omphalocoele (portion of protruding intestine) and one fetus at 750 mg/kg bw/day showed spina bifida (lower spine exposed).
Visceral Examination
The type, incidence and distribution of visceral findings at 100, 300 and 750 mg/kg bw/day did not indicate any obvious effect on fetal development. The previous external findings of one fetus at 300 mg/kg bw/day showing omphalocoele (portion of protruding intestine) and one fetus at 750 mg/kg bw/day showing spina bifida (lower spine exposed) were confirmed.
Skeletal Examination
The type, incidence and distribution of skeletal findings at 100, 300 and 750 mg/kg bw/day did not indicate any adverse effect on fetal development.
At 750 mg/kg bw/day, the incidences of fetuses showing incomplete ossification of a number of skull bones (nasal, frontal, parietal, interparietal, squamosal, jugal, zygomatic process of maxilla, zygomatic process of maxilla and hyoid) were statistically significantly lower than control. Additionally statistically significant lower incidences of incomplete ossification of the sacral (neural) arch, pubis and metacarpels were also apparent and there was a statistically significant higher incidence of foetuses with one or more ossified forepaw phalanges at this dosage.
At 300 mg/kg bw/day, statistically significant differences from control in the incidence of skeletal findings were restricted to lower incidences of fetuses showing incomplete ossification of the parietal, jugal, zygomatic process of maxilla, sacral (neural) arch and pubis.
At 100 mg/kg bw/day, the incidences of fetuses showing incomplete ossification of the hyoid and pubis were statistically significantly lower than control.
Conclusion
Based on these findings of this pre-natal study, a dosage of 750 mg/kg bw/day was regarded as a No Observed Adverse Effect Level (NOAEL) for the pregnant female.
The findings observed for fetuses at 750 mg/kg bw/day were considered to be unrelated to treatment and this dosage of 750 mg/kg bw/day was considered to represent at least a NOAEL, and most probably a No Observed Effect Level (NOEL), for the survival, growth and development of the conceptus.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.

Route: .live1